Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027686 | 0.85 | POLB (0.52) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL17113709 | 0.80 | POLB (0.54) | POLBALDH1A1 | |
| SCHEMBL21225975 | 0.79 | GRM5 (0.50) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL3947734 | 0.79 | VNN1 (0.37) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL4550437 | 0.79 | CYP3A4 (0.43) | CYP1A2ALDH1A1CYP2D6VNN1EPHX2 | |
| SCHEMBL12895649 | 0.78 | CYP2C9 (0.51) | CYP1A2CYP2C9ALDH1A1CYP2D6TSHR | |
| SCHEMBL17035434 | 0.78 | POLB (0.48) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL17176082 | 0.76 | POLB (0.56) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL26650416 | 0.76 | POLB (0.62) | POLBCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL22991226 | 0.74 | RIPK1 (0.38) | CYP2C9ALDH1A1VNN1EPHX2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268894-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4558507-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | claimed |
| EP-4558507-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268894-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, CCNA1 | POLB 2626/4885CYP1A2 313/4885CYP2C9 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.